Loading organizations...

Lunaphore is a technology company.
Lunaphore offers advanced spatial biology solutions, delivering automated multiplex immunofluorescence and immunohistochemistry platforms for comprehensive tissue analysis. Their COMET system integrates precise liquid handling with high-resolution imaging, enabling rapid, high-plex protein and RNA analysis directly on tissue. This technology provides an efficient, end-to-end workflow for biological studies.
The company was founded in 2014 as an EPFL spin-off by Ata Tuna Ciftlik, Diego Dupouy, and Déborah Heintze. Their core innovation stemmed from optimizing the tissue staining process, allowing for -omics-like approaches to traditional samples. This addressed critical limitations in spatial resolution and multiplexing, fostering a more profound biological understanding.
Lunaphore's platforms serve translational and immuno-oncology researchers, supporting discovery and targeted treatment development. The company's vision aims to empower the scientific community by making sophisticated spatial biology broadly accessible across all laboratories. They unlock deeper biological insights from tissue samples, accelerating medical research and enhancing patient care.
Lunaphore has raised $133.2M across 8 funding rounds.
Lunaphore has raised $133.2M in total across 8 funding rounds.
Lunaphore has raised $133.2M in total across 8 funding rounds.
Lunaphore's investors include Dominik Sauter, Norgine Ventures, OCCIDENT, PHC Holdings Corporation, Redalpine, Swiss Entrepreneurs Fund, Redalpine Venture Partners, Didier Denat, Michael Kloss, Alpana Ventures, Cedric Barra, Z%C3%BCrcher%20Kantonalbank.
Lunaphore is a Swiss spatial biology company that builds automated, microfluidics‑based multiplex immunofluorescence and IHC instruments and workflows to enable high‑plex proteomic and transcriptomic analysis of tissues for translational research and immuno‑oncology (now a Bio‑Techne brand after acquisition). [5][4]
High‑Level Overview
For a portfolio company (Lunaphore as a product company)
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick reminder: Lunaphore’s publicly stated capabilities and strategic position as of its Bio‑Techne acquisition form the basis for this profile; recent product launches and partnerships (including automated hyperplex workflows and AI collaborations) show continued momentum under Bio‑Techne’s ownership.[4][2][6]
Lunaphore has raised $133.2M across 8 funding rounds. Most recently, it raised $54.4M Debt / Series D in March 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 24, 2023 | $54.4M Debt / Series D | Dominik Sauter | Norgine Ventures, OCCIDENT, PHC Holdings Corporation, Redalpine, Swiss Entrepreneurs Fund |
| Mar 1, 2023 | $33.0M Series D | Redalpine Venture Partners | |
| Apr 23, 2020 | $2.1M Series C | Didier Denat | |
| Feb 1, 2020 | $24.0M Series C | Michael Kloss | Redalpine Venture Partners, Alpana Ventures, OCCIDENT |
| Aug 30, 2018 | $5.5M Series B | Cedric Barra, Z%C3%BCrcher%20Kantonalbank | |
| Oct 6, 2017 | $6.1M Other Equity | C%C3%A9r%C3%A9sia, OCCIDENT, Polytech Ecosystem Ventures, Michael Sidler | |
| Jul 1, 2017 | $6.0M Series A | Redalpine Venture Partners | |
| Apr 30, 2015 | $2.1M Series A | Michael Sidler |